Rebiotix (MN, USA) recently announced positive preliminary results from an ongoing clinical trial investigating the use of an investigational microbiota-based formulation, RBX2660, for the reduction of C. diff infection.
Browsing: Basic > Drug Development
Take a look behind the scenes of a recent Future Virology paper, titled ‘Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection: Let the…
Researchers from Princeton University have uncovered an antibiotic molecule capable of killing both Gram-negative and Gram-positive bacteria using two simultaneous mechanisms, while also avoiding antibiotic resistance.
A drug repurposing survey has identified 30 existing drugs, previously approved for treatment in other diseases, that could be successful in treating COVID-19.
The Anticancer Fund has created an open-access, online database called Covid19db, which shows the COVID-19 clinical trials currently taking place. The database has detected over 200 clinical trials across 35 countries, testing 102 different investigational drugs.
A vaccine against MERS has shown promise in mouse models, potentially aiding the development of a vaccine against COVID-19.
A new study suggests that a human recombinant soluble enzyme blocker, hrsACE2, significantly reduces SARS-CoV-2 viral load in human tissue, suggesting it could have the potential to prevent COVID-19.
Take a look behind the scenes of a recent Future Virology editorial entitled, ‘An insight into dengue virus proteins as potential drug/vaccine targets’, as we ask author Muhammad Faheem about recent advances in understanding dengue proteins and where the next 5–10 years could take us.